Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Brinker International

Big downward moves reflected downbeat news from two well-known companies.

Why 2 Key Stocks Plunged in Premarket Trading Wednesday

Biogen

Netflix

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These are the stocks posting the largest moves before the bell.

Stocks making the biggest moves before the bell: Biogen, Novavax, Netflix, Verizon & more

A report says Novavax has failed to produce a vaccine with the purity levels demanded by the Food and Drug Administration.

Novavax Stock Sinks on Report of Covid-19 Vaccine Manufacturing Problems

Shares of Novavax, Inc. (NASDAQ: NVAX), which is facing an inordinate delay in getting authorization for its COVID-19 vaccine, are moving sharply lower Wednesday. Novavax Reportedly Facing Concerning Manufacturing Issues: Amid the delay in authorization, reports suggest the company is facing issues with the purity of the vaccine candidate.

Novavax Shares Plunge To Lows Since Mid-May As COVID-19 Vaccine Woes Continue

Novavax NVAX, -3.43% shares tumbled 16% in premarket action after Politico reported it faces significant hurdles in proving it can manufacture a shot that meets regulators' quality standards, citing three people with direct knowledge of the company's problems. The report said Novavax's troubles mean the international consortium known as COVAX is now likely to fall short of its 2 billion dose target to lower and middle-income countries by the end of 2022 by more than 1 billion doses.

Novavax shares tumble after report on vaccine manufacturing difficulties

GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021

Moderna

Ocugen, Inc.

These COVID-19 vaccine makers are sinking on nothing more than good old-fashioned uncertainty.

Why Shares of Moderna, Novavax, and Ocugen Are Falling Today

GAITHERSBURG, Md., Oct. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D.

Novavax to Participate in World Vaccine Congress Europe

Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space.

Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?

The sell-off of this vaccine stock appears to be overdone.

Why Novavax Stock Is Absurdly Cheap Right Now

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

NVAX stock is up 3,480% in two years but the real price fight is awaiting headlines from management. Meanwhile, owning it requires conviction.

Novavax Stock Fortunes Are Still Awaiting the Magical Headline

The biotech looks poised -- at last -- to thrive and generate significant revenue growth.

2 Reasons to Buy Novavax Stock Now and 1 Reason to Skip It

Vaxart

Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnered with Bharat Biotech.

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up

NVAX stock has been making some volatile moves in 2021. And that volatility will continue until its Covid-19 vaccine gets regulatory approval.

Novavax Will Be Volatile Until the Company Delivers Answers

Down nearly 40% over the past month, NVAX stock has been on a steep decline that appears to be accelerating. At its current price of $163.06 per share, Novavax's stock is now 50% below its all-time high of $331.68 reached in February of this year.

Novavax Stock Will Find Its Bottom, But Probably not Soon

NVAX stock still has plenty of value as Novavax has a rich and diverse clinical pipeline, including a promising influenza vaccine candidate. The post Novavax Stock Got Merck-ed, but Don't Dump Your Shares Now appeared first on InvestorPlace.

Novavax Stock Got Merck-ed, but Don't Dump Your Shares Now

The bigger winner since early last year could still be the best pick over the near term.

Better Vaccine Stock: Moderna or Novavax?

On Thursday, Novavax Inc. (NASDAQ:NVAX) shares edged lower 1.75% after announcing a covid vaccine manufacturing deal. The company signed an agreement with Polish biotech firm Mabion SA to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373.

Should you invest in Novavax shares after inking a covid vaccine manufacturing deal?

Moderna is the most effective COVID-19 vaccine, based on the latest CDC data.

Novavax Vs. Moderna Stock: Which Is The Better Buy?

There are plenty of reasons to stay invested in NVAX stock as the Delta variant forces a renewal of fortunes for the vaccine also-ran. The post Novavax Stock Looks Interesting as the World Still Needs Vaccines appeared first on InvestorPlace.

Novavax Stock Looks Interesting as the World Still Needs Vaccines

With a new oral antiviral drug by Merck potentially over the horizon, NVAX stock may be trading on borrowed time. The post Once-Cinderella Novavax Stock Could Be Poisoned by Merck's Covid Pill appeared first on InvestorPlace.

Once-Cinderella Novavax Stock Could Be Poisoned by Merck's Covid Pill

Brookdale Senior Living

Editas Medicine

Investors craving treats should look elsewhere this month.

3 Spooky Healthcare Stocks I Would Avoid in October

AstraZeneca

Johnson & Johnson

Pfizer

It'll likely push the revenue of vaccine victors even further.

What Do Mix-and-Match Doses Mean for Vaccine Stocks?

Three Motley Fool contributors think these biotech stocks should be big winners.

News for Novavax Stock (NVAX)